OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Eng on Real-World Outcomes in US Patients With KRAS G12C–Mutated CRC

July 16th 2025

Cathy Eng, MD, FACP, FASCO, discusses a real-world study of the effect of KRAS G12C mutations on outcomes in patients with metastatic colorectal cancer.

Dr Thaker on IMNN-001 Plus Neoadjuvant Chemo in Newly Diagnosed Ovarian Cancer

July 16th 2025

Premal H. Thaker, MD, MS, discusses data from a study of IMN-001 plus neoadjuvant chemotherapy in newly diagnosed epithelial ovarian cancer.

Dr Martini on the Evolving Role of Intravesical Therapies in High-Risk NMIBC

July 16th 2025

Alberto Martini, MD, discusses the evolving role of intravesical therapies in patients with high-risk non–muscle-invasive bladder cancer.

Dr Klempner on Data for Givastomig Plus Nivolumab/mFOLFOX in Metastatic Gastric, Esophageal, and GEJ Adenocarcinoma

July 16th 2025

Samuel J. Klempner, MD, discusses the safety and efficacy of givastomig plus nivolumab and chemotherapy in metastatic gastric cancers.

Dr Wilky on the Role of Personalized Therapy in GIST

July 16th 2025

Breelyn Wilky, MD, details personalized therapy approaches for the treatment of patients with GIST.

Dr Weinberg on the Implications of Data With BXCL701 Plus Pembrolizumab in mPDAC

July 15th 2025

Benjamin A. Weinberg, MD, FACP, discusses the clinical implications of data with BXCL701 plus pembrolizumab in metastatic pancreatic ductal adenocarcinoma.

Dr Mayadev on a ctDNA Analysis of the CALLA Trial in Cervical Cancer

July 15th 2025

Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.

Dr McArthur on Monitoring for ILD When Administering T-DXd in HER2+ Breast Cancer

July 15th 2025

Heather McArthur, MD, discusses monitoring strategies for interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

July 15th 2025

Amrita Krishnan, MD, discusses data for elranatamab plus daratumumab and lenalidomide in newly diagnosed, transplant-ineligible multiple myeloma.

Dr Singhi on the Rationale for Evaluating Lurbinectedin Plus Atezolizumab in ES-SCLC

July 15th 2025

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Dr Jones on the Implications of Data from ASCENT-04 for First-Line PD-L1+ TNBC Management

July 15th 2025

Jade E. Jones, MD, discusses the importance of identifying the most effective first-line treatment regimen for PD-L1–positive TNBC.

Dr Qin on Ongoing Investigations of Radium-223 in mCRPC

July 15th 2025

Qian (Janie) Qin, MD, discusses efforts to elucidate the optimal use of radium 223 plus enzalutamide in metastatic castration-resistant prostate cancer.

Dr Logan on Obe-Cel as a Potential Definitive Treatment in R/R B-ALL

July 15th 2025

Aaron C. Logan, MD, PhD, discusses the potential use of obe-cel as definitive treatment in adult relapsed/refractory B-ALL.

Dr Jordan on Challenges With Drug Development in Adult NF1-Associated PN

July 15th 2025

Justin T. Jordan, MD, MPH, FAAN, discusses treatment challenges and recent progress made with targeted therapies in adult NF1-associated PNs.

Dr Randall on Addressing Disparities in Access to Specialized Sarcoma Care

July 14th 2025

R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.

Dr Kamdar on Patient Monitoring After Liso-Cel in MCL and Hematologic Malignancies

July 14th 2025

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.

Dr Huppert on Evolving First-Line Treatment Standards for HER2+ Metastatic Breast Cancer

July 14th 2025

Laura Huppert, MD, discusses ways that the frontline use of T-DXd in HER2-positive metastatic breast cancer may affect later-line treatment decisions.

Dr Bekaii-Saab on the Expanding Targeted Therapy Paradigm for Biliary Tract Cancers

July 14th 2025

Tanios S. Bekaii-Saab, MD, discusses current and emerging therapeutic targets for the treatment of patients with biliary tract cancers.

Dr Munir on a MAIC of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax in CLL

July 11th 2025

Tahla Munir, MBChB, PhD, discusses the rationale for a MAIC of the phase 3 SEQUOIA and AMPLIFY trials in chronic lymphocytic leukemia.

Dr Lee on the Future Development of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer

July 11th 2025

Elizabeth Lee, MD, discusses the future of Rina-S in FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.